Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.
Department of Radio Diagnosis, All India Institute of Medical Sciences, New Delhi, India.
J Crohns Colitis. 2024 Feb 26;18(2):192-203. doi: 10.1093/ecco-jcc/jjad135.
Thiopurines are viable option for the treatment of inflammatory bowel disease [IBD] in resource-limited countries. However, data on the effect of disease duration at thiopurines initiation on long-term effectiveness are limited.
We performed a propensity matched analysis of a retrospective cohort of patients with ulcerative colitis [UC] and Crohn's disease [CD]. Patients initiated on thiopurines early in the disease course [≤2 years] were compared with those started late [>2 years]. Effectiveness was defined as no requirement for hospitalisation, anti-tumour necrosis factor [TNF] agents, or surgery, and minimum steroid requirement [≤1 steroid course in 2 years] during follow-up.
A total of 988 [UC: 720, CD: 268] patients were included (male: 665 [60.8%], median age: 40 [32-51] years, median follow-up: 40 [19-81] months). Overall effectiveness at 5 and 10 years was 79% and 72% in UC, and 69% and 63% in CD, respectively. After propensity score matching, there was no difference in 5- and 10-year effectiveness between early and late thiopurine initiation groups either for UC [81% and 80% vs 82% and 74%; p = 0.92] or CD [76% and 66% vs 72% and 51%, p = 0.32]. Male sex for UC (negative: hazard ratio [HR]: 0.67, 95% confidence interval [CI): 0.45-0.97; p = 0.03), and ileal involvement [positive: HR: 3.03, 95% CI: 1.32-6.71; p = 0.008], steroid-dependent disease [positive: HR: 2.70, 95% CI: 1.26-5.68; p = 0.01] and adverse events [negative: HR: 0.47, 95% CI:0.27-0.80; p = 0.005] for CD were predictors of thiopurine effectiveness.
Thiopurines have sustained long-term effectiveness in both UC and CD. However, early thiopurine initiation had no better effect on long-term disease outcome compared with late initiation.
硫嘌呤类药物是资源有限国家治疗炎症性肠病[IBD]的可行选择。然而,关于硫嘌呤类药物起始时疾病持续时间对长期疗效的影响的数据有限。
我们对溃疡性结肠炎[UC]和克罗恩病[CD]患者的回顾性队列进行了倾向评分匹配分析。将疾病早期[≤2 年]开始使用硫嘌呤类药物的患者与疾病晚期[>2 年]开始使用硫嘌呤类药物的患者进行比较。疗效定义为在随访期间无需住院、使用抗肿瘤坏死因子[TNF]药物或手术,以及类固醇最低需求[2 年内≤1 个疗程类固醇]。
共纳入 988 例[UC:720 例,CD:268 例]患者(男性:665 例[60.8%],中位年龄:40 [32-51]岁,中位随访时间:40 [19-81]个月)。UC 患者的 5 年和 10 年总有效率分别为 79%和 72%,CD 患者分别为 69%和 63%。在进行倾向评分匹配后,UC 患者的早期和晚期硫嘌呤类药物起始组在 5 年和 10 年的疗效方面无差异[81%和 80%与 82%和 74%;p=0.92],CD 患者也无差异[76%和 66%与 72%和 51%;p=0.32]。UC 患者的男性性别[负:风险比[HR]:0.67,95%置信区间[CI]:0.45-0.97;p=0.03],回肠受累[正:HR:3.03,95%CI:1.32-6.71;p=0.008],类固醇依赖疾病[正:HR:2.70,95%CI:1.26-5.68;p=0.01]和不良事件[负:HR:0.47,95%CI:0.27-0.80;p=0.005]是硫嘌呤类药物疗效的预测因素。
硫嘌呤类药物在 UC 和 CD 中均具有长期疗效。然而,与晚期起始相比,早期起始硫嘌呤类药物对长期疾病结局没有更好的效果。